Lenacapavir, a twice-yearly injectable HIV-1 capsid inhibitor, has shown 100% efficacy in preventing HIV in women at a high risk for infection, according to an interim analysis of the phase 3 PURPOSE 1 trial. The results were so promising that the independent data monitoring committee recommended that Gilead Sciences stop the blinded phase of the […]